Purpose: The main purpose of the study was to determine the safety profile and efficacy of intravenous ibuprofen administered over 5 to 10 minutes for the treatment of pain or fever in hospitalized patients. Current evidence supports the use of intravenous infusions of ibuprofen to control pain and reduce the opioid requirements associated with surgical pain. Current dosing guidelines recommend that the drug be administered over 30 minutes. However, a more rapid infusion might yield additional benefits. The safety profile and efficacy of a shortened infusion time requires additional study.
INTRODUCTION
Pain and fever in the hospital setting are conditions that require prompt and effective treatment to achieve and maintain patient comfort. [1] [2] [3] Patient comfort and symptom resolution play key roles in the recovery and healing of hospitalized patients and are therefore important in determining length of hospital stay. 4, 5 Oral nonsteroidal antiinflammatory drugs (NSAIDs) have been used for many years to treat pain and fever in the hospital setting, but a large percentage of these patients are often unable to take oral medications due to intubation or unconsciousness. 3, 6, 7 In addition, the absorption and metabolism of oral drugs in hospitalized patients can differ greatly from the nonhospitalized population, leading to altered blood levels of the drug and potential concerns about efficacy and tolerability. 8 These issues can make the intravenous route a more suitable option for hospitalized patients. In 2009, the US Food and Drug Administration approved intravenous ibuprofen for the treatment of mild to moderate pain, moderate to severe pain as an adjunct to opioids, and fever. Previous clinical trials of intravenous ibuprofen administered over 30 minutes have shown intravenous ibuprofen to be well tolerated and effective. [9] [10] [11] However, a shortened infusion time has the potential to further accelerate the onset of action of intravenous ibuprofen; achieve higher peak blood levels, which can potentiate the analgesic, antipyretic, and anti-inflammatory effects; and decrease the time burden on the medical staff administering the drug. 12 Recently, a Phase I study in 12 healthy subjects examined a 5-to 7-minute infusion time of intravenous ibuprofen and found the shortened infusion time to be well tolerated. 13 Subsequently, this Phase IV multicenter, open-label safety surveillance study was one of two prospective studies designed to evaluate the safety profile of a shortened infusion time. The present study was designed to further evaluate the safety profile of the rapid 5-to 10-minute infusion of intravenous ibuprofen in hospitalized patients already experiencing pain or fever, or both.
METHODS
This Phase IV multicenter, open-label, single-dose, and multiple-dose surveillance clinical study was conducted to assess the safety profile and efficacy of ibuprofen administered intravenously over 5 to 10 minutes to adult patients with fever (temperature >1011F) or pain (visual analog scale [VAS] assessment >3 [30 mm]) in a hospital setting. This study was approved by site-specific Institutional Review Boards and informed patient consent was obtained from all patients before study inclusion. Hospitalized patients experiencing pain and with a baseline VAS assessment >30 mm or fever with a temperature >1011F were eligible for enrollment. Exclusion criteria included patients with inadequate intravenous access; patients younger than 18 years of age; and those with a history of allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin (or aspirin-related products), or NSAIDs. Additional exclusion criteria included active hemorrhage or clinically significant bleeding, pregnancy or nursing, and patients in the perioperative period in the setting of coronary artery bypass graft surgery. NSAIDs other than study medication were excluded during the treatment and posttreatment periods.
Eligible patients received one of two dose levels (400 mg for treatment of fever or 800 mg for treatment of pain) of intravenous ibuprofen. Patients were permitted to receive up to 5 additional doses of 400 mg (every 4 hours) or 3 additional doses of 800 mg (every 6 hours) of intravenous ibuprofen, as determined by the investigator. The drug was diluted in saline and administered at a concentration of o4 mg/mL over 5 to 10 minutes. There was no comparator arm in this study.
Assessments
To evaluate the tolerability of a single dose of intravenous ibuprofen administered over 5 to 10 minutes for the treatment of pain or fever, vital signs were recorded at baseline and 4 hours after ibuprofen infusion (after the first infusion in patients receiving multiple doses). The incidence of adverse events occurring within the 6 hours after administration of intravenous ibuprofen was also assessed. Each site investigator assessed the association between any adverse event and intravenous ibuprofen.
To evaluate the tolerability of multiple doses of intravenous ibuprofen administered over 5 to 10 minutes for the treatment of postoperative pain, the incidence of adverse events occurring within the 6 hours after administration of the last dose of intravenous ibuprofen was collected.
For patients enrolled for the treatment of fever, temperature assessments were collected frequently during the subsequent 4 hours after drug infusion. For patients enrolled for the treatment of pain, pain intensity was measured frequently during the subsequent 4 hours after the drug infusion. The pain intensity was quantified based on the patient's selfassessment using VAS from 0 to 100 mm, with 0 mm indicating no pain and 100 mm indicating intense pain.
Statistical Analysis
Formal sample size calculations were not performed. The intent was to enroll 150 patients to provide descriptive safety profile and efficacy data. Continuous data were summarized in spreadsheets listing the mean (SD), median, minimum, and maximum. Categorical data were summarized by frequencies and percentages. All data collected during the study were included in data listings. All data were listed by treatment group, treatment indication, and patient. Statistical analyses were conducted with SAS software, version 9.1.3 or higher (SAS Institute, Cary, North Carolina).
RESULTS
Thirteen clinical centers in the United States enrolled patients in this study ( Table I) . A total of 150 patients were enrolled in the study, with 11 patients enrolled for the treatment of fever and 139 enrolled for the treatment of pain (fever n ¼ 11; pain n ¼ 139). Demographic and baseline characteristics are presented in Table II . Baseline pain was divided into two categories: mild to moderate (VAS o30 to r65 mm) and moderate to severe (VAS 65 to r100 mm). Of the 150 patients enrolled in the study, 97 patients (65%) received a single dose of intravenous ibuprofen and 53 patients (35%) received multiple doses (2 or more) ( Table III) . Of the 139 patients enrolled for the treatment of pain, 79 patients (57%) were treated for postoperative pain and 60 patients (43%) were treated for nonsurgical pain (Table IV) .
Vital signs were measured at baseline and 1 hour post dose of intravenous ibuprofen. No significant differences were observed from baseline and 1 hour post dose for any vital sign other than temperature ( Table V) . Adverse events were reported for 43 of the 150 patients (29%). For the 43 patients experiencing adverse events, most patients experienced adverse events that were mild to moderate in intensity (40 of 43 patients [93%]; Table VI ). The most common adverse event experienced by patients was infusion site pain or discomfort (24 of 150 patients [16%]). Other adverse events reported by >3% of patients included flatulence, nausea, abnormal breath sounds, and hyperglycemia (Table VII) . Four (3%) patients discontinued the study drug due to infusion-site pain. One serious adverse event was reported, a case of hypotension that was deemed unrelated to intravenous ibuprofen in the investigator's assessment of the relationship (Table VI) . Table I . List of investigators and institutions participating in this multicenter study.
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Temperature assessments over the 4 hours after a dose of intravenous ibuprofen were collected for those enrolled for treatment of fever. A decrease in temperature was observed over time with a mean (SD) decrease of 1.5 (1.25)1F after 4 hours (Figure 1) .
Similarly, in patients receiving intravenous ibuprofen for management of pain, a decrease in patientreported VAS (0À100 mm) scores was observed over the 6 hours after a dose of intravenous ibuprofen, with up to a 52% decrease from the baseline pain level (Table VIII, Figure 2 ). The decrease in pain scores appeared to be more pronounced in those patients presenting with moderate to severe pain at baseline compared with those presenting with mild to moderate pain ( Figure 2) ; however, concomitant medications were not controlled, which did not allow for definitive conclusions.
DISCUSSION
The present study was one of two trials designed to assess the safety profile of a more rapid 5-to 10-minute infusion time of intravenous ibuprofen. The study population included a wide range of patient groups and clinical diagnoses, including both surgical and nonsurgical patients. Such diversity created the possibility of influence of several confounding factors on the study results, for example, use of opioids or other analgesics. However, such an approach allowed for assessing the tolerability and efficacy of the new mode of drug administration in patient categories representative of a typical major hospital. In this study, adverse events were reported in 43 of the 150 patients, with infusion-site pain (24 of 150 patients [16%]) as the most common adverse event. The infusion-site pain safety profile results from this study are consistent with other intravenous analgesic infusion pain safety profile data. Previous studies have demonstrated a range of 5% to 29% 14-16 incidence of infusion-site pain. Another injectable NSAID, ketorolac, reported injection-site pain ranging from 19% to 29%.
14 In patients receiving intravenous ibuprofen for management of pain, patient-reported mean VAS scores decreased from baseline for all time points. A mean VAS score reduction of 29% was observed from baseline to 15 minutes post dose, and up to a 52% decrease from the baseline pain level was registered during the 6-hour follow-up period. Previous studies have shown up to a 32% reduction of integrated VAS assessed at rest with use of a 30-minute infusion of intravenous ibuprofen. 9 Our study adds to the existing data and indicates that a shortened infusion time of intravenous ibuprofen can be a well tolerated and effective alternative, and yield additional benefits, such as reduced work burden and faster onset of drug action. This shortened infusion time of intravenous ibuprofen has the potential to achieve higher peak blood levels of intravenous ibuprofen at a more rapid pace, which can potentiate the analgesic, antipyretic, and antiinflammatory effects, and maximize the onset of action. Previous studies have reported on the safety profile and efficacy of shortened infusion time of intravenous ibuprofen. 9, 13 It was established that the T max of intravenous ibuprofen administered within 5 to 7 minutes equals 0.11 hour. 13 Obviously, the faster drug administration and resulting faster onset of action (as determined during the drug development phase by Cumberland Pharmaceuticals, Inc.) decreases the time burden on the medical staff administering the drug and improves the quality of patient care. Urgent pain relief is a necessity in optimizing patient comfort and improving patient outcome and, therefore, onset of action plays a critical role in treating numerous types of existing pain seen throughout the hospital, such as postsurgical pain, fractures, and neuropathic pain. 4, 5 In addition, the advent of a rapid infusion of intravenous ibuprofen could provide more timely and robust fever reduction in critically ill patients with a high fever. We think that, in addition to providing additional tolerability and efficacy data supporting the shortened infusion time of intravenous ibuprofen, it would be desirable to design a study to compare the drug kinetics, pharmacodynamic effects, and incidence of treatment-related adverse effects of 5-to 7-minute infusion with the conventional 30-minute infusion of intravenous ibuprofen. This study had several limitations. First, as an openlabel, single treatment-arm study, there was no control arm. The use of additional analgesics and antipyretics other than the study drug was permitted before the treatment period, allowing for the potential of adverse effects and efficacy results not associated with intravenous ibuprofen. Another source of variability was the wide range of pain types and differences in ibuprofen efficacy in treating the pain of different etiologies.
CONCLUSIONS
The results of this trial add to a growing body of literature that supports the tolerability and efficacy of a 5-to 10-minute infusion of intravenous ibuprofen. This study also supports the utility of intravenous ibuprofen in the management of various types of pain, including surgical and nonsurgical. A shortened infusion can aid in aggressive fever control in the acute emergency department and critical care setting. This Clinical Therapeutics study suggests that hospital protocols for pain, inflammation, and fever management could effectively adopt a shortened infusion time of intravenous ibuprofen.
